Cara Therapeutics, Inc.
CARA
株式のランク
#9881
Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating... Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating primarily within the United States. Its core business involves discovering and commercializing novel drug compounds, with a particular emphasis on addressing itching (pruritus) and pain by selectively modulating kappa opioid receptors. The company's therapeutic pipeline includes potential medicines designed to interact with the body's peripheral nervous system and immune cells. KORSUVA (difelikefalin), an injectable formulation, stands as their flagship product. It is approved for treating moderate-to-severe pruritus linked to chronic kidney disease in adult patients undergoing hemodialysis. Additionally, Cara Therapeutics is advancing an oral version of KORSUVA (difelikefalin) through its pipeline. This oral candidate has successfully completed Phase II clinical trials for relieving pruritus associated with atopic dermatitis and chronic kidney disease not requiring dialysis (NDD-CKD). It is also currently undergoing Phase II evaluation for pruritus related to chronic liver disease (specifically primary biliary cholangitis) and for notalgia paresthetica. The company has established international licensing agreements: one with Maruishi Pharmaceutical Co., Ltd for the development, production, and commercialization of difelikefalin-containing products targeting acute pain and uremic pruritus in Japan, and another with Chong Kun Dang Pharmaceutical Corporation for similar activities concerning difelikefalin products in South Korea. Cara Therapeutics, Inc. was established in 2004 and is headquartered in Stamford, Connecticut.
株価
$15.96
最終同期: 2025-04-15
時価総額
$875.31M
変化（1日）
-4.14%
変化（1年）
-0.19%
国
US
取引 Cara Therapeutics, Inc. (CARA)
カテゴリー
Healthcare
の時価総額 Cara Therapeutics, Inc.(CARA)
時価総額: $875.31M
October 2026時点で、Cara Therapeutics, Inc. の時価総額は $875.31M です。これは、当社のデータによると、Cara Therapeutics, Inc. が世界で9881st番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Cara Therapeutics, Inc. の時価総額の履歴（2018 から 2026 まで）
